CONTENTS

 

Proxy Materials for 2026 Annual General Meeting of Shareholders

 

 Evogene Ltd. (“Evogene”) hereby publishes notice of its 2026 annual general meeting of shareholders (the “Meeting”), which is scheduled to take place at 12:00 p.m. (Israel time) on Friday, September 4, 2026, at Evogene’s offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

 

 Attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is the Notice of Annual General Meeting of Shareholders, which contains information concerning the agenda for the Meeting, the required majority for approval of each proposal at the Meeting, the voting procedure, and additional general matters related to the Meeting.

 

 Attached as Exhibit 99.2 to this Form 6-K is the Company’s proxy statement for the Meeting, which describes in greater detail the proposals to be presented at the Meeting, including background information related to the proposals, additional logistical information concerning the required vote and means of voting on the proposals, and general information concerning Evogene’s board of directors and corporate governance.

 

 Attached as Exhibit 99.3 to this Form 6-K is the form of proxy card being distributed by Evogene to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposals to be presented at the Meeting.

 

 Attached as Exhibit 99.4 to this Form 6-K is a letter from Evogene’s board of directors to shareholders in connection with Proposal 1 for the 2026 annual general meeting.

 

Departure of Executive Officer

 

Evogene reports that Ms. Olga Nissan has stepped down from her position as the Company’s VP Business Development, effective as of July 31, 2026. A search for a replacement is being conducted. Evogene thanks Ms. Nissan for her service.

 

Exhibits

 

 

Incorporation by Reference

 

 The contents of this Form 6-K, as well as Exhibits 99.1, 99.2, and 99.3 hereto, are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission File No.’s 333-277565 and 333-294650), and Form S-8 (SEC File No.’s 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Signature